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Mineralocorticoid receptor antagonists (MRAs) improve outcomes in patients with systolic heart failure (HF) and mild symptoms. MRAs may induce worsening of renal function (WRF) and hyperkalemia (HK),1,2 both of which 
are associated with adverse outcomes.2–5 More generally, 
WRF and HK associated with renin angiotensin aldosterone 
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Background—Mineralocorticoid receptor antagonists improve outcomes in patients with systolic heart failure but may 
induce worsening of renal function (WRF) and hyperkalemia (HK). We assessed the risk factors for mineralocorticoid 
receptor antagonist–related WRF and for HK, as well as the association between HK and WRF with clinical outcomes in 
the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF).
Methods and Results—Serial changes in estimated glomerular filtration rate and in serum potassium were available in 2737 
patients during a median 21-month follow-up. HK variably defined as serum K >4.5, 5, or 5.5 mmol/L occurred in 74.7%, 
32.5%, and 8.9% patients enrolled in EMPHASIS-HF, respectively. WRF defined as a decrease in estimated glomerular 
filtration rate >20% or >30% from baseline occurred in 27% and 14% of patients, respectively. Patients assigned 
eplerenone displayed modest and early but significant and persistent (1) rise in serum potassium and (2) reduction in 
estimated glomerular filtration rate when compared with those assigned placebo. In multivariate analyses, eplerenone was 
associated with a higher incidence of WRF and HK, which were interrelated and also associated with baseline patient 
characteristics (eg, age ≥75 years, hypertension, diabetes mellitus, nonwhite race, ejection fraction <30%, and treatment 
with an antiarrythmics drug or loop diuretic). Eplerenone retained its survival benefits without any significant interaction 
with the association between HK >5.5 mmol/L only and WRF and worse outcomes.
Conclusions—In patients with heart failure receiving optimal therapy, WRF and HK were more frequent when eplerenone 
was added, but their occurrence did not eliminate the survival benefit of eplerenone.
Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT00232180.   
(Circ Heart Fail. 2014;7:51-58.)
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system (RAAS) blockade6,7 are pertaining to physicians 
and prevent many from appropriately implementing these 
life-saving drugs in patients with HF.8 Little is known about 
the inter-relationships between WRF and HK in patients 
with HF receiving RAAS inhibitors or the influence these 
adverse events may have on clinical benefits derived from 
MRA therapy.
The Eplerenone in Mild Patients Hospitalization and 
Survival Study in Heart Failure (EMPHASIS-HF) inves-
tigated the effects of the MRA eplerenone, added to 
 evidence-based therapy including RAAS inhibitors and 
β-blockers on clinical outcomes, in patients with systolic HF 
and mild symptoms (ie, New York Heart Association func-
tional class II symptoms). Eplerenone reduced the primary 
end point of cardiovascular death or HF hospitalization and 
the secondary end point of all-cause mortality in comparison 
with placebo when added to evidence-based therapy. HK and 
WRF were reported as adverse events by investigators. HK 
was more common in the eplerenone group than in the pla-
cebo group (8% versus 3.7%; P<0.001).1 However, HK lead-
ing to treatment discontinuation was no more frequent in the 
eplerenone group (1.1% versus 0.9%; P=0.57). The incidence 
of WRF and the rate of discontinuation because of WRF did 
not differ between treatment groups.1 Hospitalization for 
WRF or HK was adjudicated and neither differed between 
treatment groups. No death was attributed to WRF or HK. 
Because of protocol-mandated serial monitoring of serum 
creatinine and potassium, we have also been able to look at 
actual changes in renal function and potassium, as opposed 
to just investigator-reported events. We evaluated the deter-
minants, interactions, and prognostic significance of WRF 
and HK in patients enrolled in EMPHASIS-HF. We also 
evaluated the interaction among WRF, HK, and the effect of 
eplerenone on clinical outcomes.
Methods
Study Design and Patient Population
The design and main results of the EMPHASIS-HF trial have been re-
ported previously.9 The study was approved by an institutional review 
committee, and the subjects gave informed consent. We performed a 
post hoc analysis in all 2737 patients included in the EMPHASIS-HF 
trial. Median follow-up was 21 months. Per-protocol dosing require-
ments based on the estimated glomerular filtration rate (eGFR)10 and 
serum potassium are shown in Table 1.1
The first objective was to determine the risk associated with HK 
defined as >4.5, >5, or >5.5 mmol/L (the latter being the cutoff used 
in the protocol for dose reduction), taking into account the possible 
occurrence of WRF and eplerenone intake. The incidence and deter-
minants of HK or WRF (defined as a decrease in eGFR >20%2,11 or 
>30%12 from baseline) are also evaluated.
Statistical Analysis
All analyses were performed using SAS version 9.1 software (SAS 
Institute, Cary, NC). P values were 2 sided with statistical signifi-
cance defined as P<0.05. There were no adjustments for multiple 
comparisons given the post hoc exploratory nature of the analyses. 
There was no prespecified hierarchical ordering of the analyses.
To examine how serum potassium and eGFR changed over time, 
repeated-measures ANCOVA models were fit with model terms for 
treatment group, time point, treatment by time point interaction, and 
baseline using SAS PROC MIXED. A heterogeneous compound 
symmetrical covariance structure was fit to the residual error. The 
adjusted means at each time point were compared between treatment 
groups using t statistics from the repeated-measures model using the 
DIFF option of the LSMEANS statement. The average annual chang-
es in serum eGFR from baseline to month 29 were calculated for each 
subject as the slopes of the regression lines using time in years as 
the independent variable. Summary statistics were calculated, and the 
mean annual change was compared between treatments using t tests. 
Pearson correlations between serum potassium and eGFR levels were 
calculated for each time point separately and tested for significance 
using t statistics.
Time-to-event analyses were performed using the Cox regression 
model. Covariables were entered using a forward selection method, 
with the final models retaining only the significant factors. In the ab-
sence of a clinically prespecified cut point for continuous variables, 
we chose medians. The validity assumptions of the Cox regression 
were checked (ie, proportionality of hazards and absence of collinear-
ity or interaction).
Three types of analyses were performed. First, the association of 
HK with the first occurrence of WRF (as time-dependent covariate) 
was evaluated, with adjustment for treatment group and ≤4 significant 
covariates (baseline eGFR, baseline serum potassium, hypertension, 
and ethnicity) depending on the definition of HK.
Second, the association of WRF with the first occurrence of HK (as 
time-dependent covariate) was evaluated, with adjustment for treat-
ment group and ≤6 significant covariates (age, baseline eGFR, diabe-
tes mellitus, ejection fraction [EF] <30%, use of antiarrhythmics, and 
use of diuretics) depending on the definition of WRF.
Third, the association between the first occurrence of HK and WRF 
(as time-dependent covariates) and 5 clinical outcomes (HF hospi-
talization/cardiovascular death, HF hospitalization, cardiovascular 
death, all-cause death, and sudden cardiac death) was evaluated with 
adjustment for treatment group, and 11 covariates found to be signifi-
cantly associated with the primary outcome, including age (<75 and 
≥75 years), baseline eGFR (≤median and >median), diabetes melli-
tus, presence of left bundle branch block, sex, mean arterial pressure 
(≤median and >median), use of potassium supplements, target dose 
of β-blockers at randomization (<50% and ≥50%), use of antiarrhyth-
mics, use of diuretics, and ethnicity (white versus other). Five addi-
tional covariates were tested but not found significant: baseline serum 
potassium (≤4.5 and >4.5 mmol/L), EF <30%, hypertension, target 
dose of angiotensin-converting enzyme inhibitor at randomization 
(<50% and ≥50%), and target dose of angiotensin receptor blocker at 
randomization (<50% and ≥50%).
Table 1. Eplerenone Titration Algorithm Used in EMPHASIS-HF
Eplerenone Dose
Threshold for eGFR or serum 
potassium
  eGFR ≥50 mL/min per 1.73 m2 Start with 25 mg once daily and 
increased after 4 wk to 50 mg 
once daily if serum potassium was 
≤5 mmol/L
  eGFR 30 to 49 mL/min per 
1.73 m2
Start with 25 mg once every other day 
and increased after 4 wk to 25 mg 
once daily if serum potassium was 
≤5 mmol/L
Guidelines for follow-up (patients 
monitored) after 1 wk, 1 mo, and 
every 4 mo thereafter
  Potassium 5.5–5.9 mmol/L at 
any follow-up time point
Decrease the dose of study drug
  Potassium ≥6 mmol/L at any 
follow-up time point
Withhold study drug and restart only 
if potassium (remeasured within 72 h) 
was <5 mmol/L
eGFR indicates estimated glomerular filtration rate; and EMPHASIS-HF, 
Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure.
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Results
Long-Term Effects of Eplerenone on Serum 
Potassium and on Kidney Function
Compared with placebo, eplerenone induced an early but 
modest rise in serum potassium (Figure [A]) and decline in 
eGFR (Figure [B]). Both changes persisted thereafter. The 
mean (confidence interval) annual rate of change in eGFR 
was −0.288 mL/min per 1.73 m2 (−0.395 to −0.182) in the 
eplerenone group and −0.066 mL/min per 1.73 m2 (−0.174 
to −0.042) in the placebo group (P=0.004 between groups). 
Throughout the study, eGFR and serum potassium were sig-
nificantly but weakly negatively correlated (Figure [C]).
Frequency Distributions and Determinants of 
Increases in Serum Potassium and Worsening  
Renal Function
HK occurrence at any time during follow-up was common, 
with 74.7% of patients experiencing serum potassium >4.5 
mmol/L (eplerenone, 80%; placebo, 69.4%; P<0.001) and 
32.5% with serum potassium >5 mmol/L (eplerenone, 37.9%; 
placebo, 27.1%; P<0.001). Serum potassium >5.5 mmol/L 
was less common (8.9%; eplerenone, 11%; placebo, 6.8%; 
P<0.001). A >20% reduction of eGFR occurred in 27.2% of 
patients (eplerenone, 30.1%; placebo, 24.4%; P<0.001), and 
a >30% reduction of eGFR occurred in 14.0% of patients 
(eplerenone, 16.1%; placebo, 11.9%; P=0.002).
In multivariate analysis, a lower baseline eGFR (below the 
median of 68 mL/min per 1.73 m2), serum potassium >4.5 
mmol/L at baseline, hypertension, eplerenone treatment 
group, and the first occurrence of WRF (>20% or 30% decline 
in eGFR) were independently associated with the develop-
ment of HK of >5 or >5.5 mmol/L (Table 2). A higher eGFR 
(greater than the median) at baseline, eplerenone group, and 
the first occurrence of HK >5 or >5.5 mmol/L were asso-
ciated with incident WRF (either >20% or >30% decline in 
eGFR), independent from other predictors in the model, that 
is, older age, diabetes mellitus, and the use of antiarrhyth-
mic agents (and of diuretics and an EF <30% for WRF >20% 
only; Table 3).
Eplerenone Exerts a Beneficial Effect on Clinical 
Outcomes, Independent of HK >5.5 mmol/L or 
Worsening Renal Function
We performed a multivariate analysis, adjusting for several 
baseline covariates, including HK, WRF, and eplerenone 
treatment (Table 4). Sudden cardiac death was not signifi-
cantly associated with any of these 3 factors and is not dis-
cussed further.
Eplerenone was independently and consistently associated 
with a beneficial effect on all 4 outcomes shown in Table 4. 
HK was generally not associated with worse outcomes with 
the exception of potassium >5.5 mmol/L, which was associ-
ated with an increased risk of all-cause death. By contrast, 
the occurrence of WRF was associated with more frequent 
occurrence of all 4 outcomes regardless of the definition used 
for WRF. Systematic interaction assessments showed that the 
effects of eplerenone on outcomes did not significantly change 
in the setting of HK or WRF regardless of the threshold used 
to define HK or WRF events (eg, P values of the interaction 
assessments between 0.31 and 0.72; for the HF hospitaliza-
tion/cardiovascular death outcome, see the Data Supplement).
Discussion
The present study provides important insights into kidney 
function and serum potassium variations and their relationship 
with outcomes in patients with HF, low EF, and mild symp-
toms treated with RAAS inhibitors. When compared with 
placebo-treated patients, eplerenone-treated patients exhib-
ited an early, modest, and sustained but statistically significant 
(1) decline in eGFR and (2) rise in serum potassium. Both 
HK and WRF were significantly more frequent in the eplere-
none group, but eplerenone treatment was only one of several 
contributors to these biochemical changes. Other independent 
predictors included older age, baseline eGFR, baseline potas-
sium, hypertension, diabetes mellitus, and antiarrhythmic 
drug use (Tables 2 and 3). The beneficial effect of eplerenone 
was consistent (23%–41% improvement in the tested out-
comes) and independent of the occurrence of HK and WRF, 
and no significant interaction with HK and WRF was detected 
(Data Supplement). A rise in serum potassium at anytime dur-
ing the study to >5.5 mmol/L was a rare event, occurring in 
<9% of patients, but it was associated with a higher risk of 
deaths. A decline in eGFR exceeding 20% or 30% was inde-
pendently associated with a more frequent occurrence of all 
clinical outcomes.
These results have major clinical implications. First, 
eplerenone retained its clinical benefit, despite being asso-
ciated with more frequent WRF (defined as either a >20% 
or >30% decline in eGFR) and HK, both of which (HK 
>5.5 mmol/L) were independently associated with worse 
outcomes without any significant interaction with eplere-
none. This finding suggests that strict adherence to the 
inclusion criteria, dosing, and monitoring regimens used 
in EMPHASIS-HF (Table 1) should be applied in clinical 
practice to realize the positive benefit/risk ratio achieved 
by eplerenone in the clinical trial. One might also suggest 
that an increase in serum K+ >5.5 mmol/L or WRF occur-
ring in patients on eplerenone should prompt closer monitor-
ing of serum K+ and renal function (eg, at 1 week, 2 weeks, 
and then monthly for ≥3 months to assure stability). But 
in view of the beneficial effects of eplerenone on mortal-
ity and morbidity, despite the occurrence of HK or WRF, 
one should consider lowering the dose of eplerenone but not 
stopping it. Second, these data suggest that a threshold of 
5.5 mmol/L may represent a clinically meaningful definition 
of HK (because this threshold was associated with adverse 
clinical outcomes; Table 1). This is at variance with the 
current American College of Cardiology/American Heart 
Association guidelines stating that serum potassium concen-
trations should be targeted to <5.0-mEq/L threshold,13 and 
the European Society of Cardiology guidelines recommend 
cautious use with serum potassium >5.0 mmol/L.14
Whether even closer monitoring of serum potassium 
and of eGFR variations from baseline (not only consider-
ing eGFR itself because it was performed herein within the 
titration algorithm) could further improve patient outcomes, 
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especially in patients with baseline features associated with 
HK or WRF occurrences (ie, older age ≥75 years, hyperten-
sion or diabetes mellitus history, nonwhite race, lower EF 
<30%, antiarrythmics, and loop diuretic intake), warrants 
further prospective studies.
This is the first report of the effects of an MRA when com-
pared with placebo on long-term serial changes of both kidney 
function and serum potassium in patients with chronic HF and 
mild symptoms. In EMPHASIS-HF, eplerenone induced an 
early and modest but statistically significant decline in eGFR, 
Potassium (mmol/L)A
B
C
r = pearson correlation
eGFR (ml/min/1.73m2)
eGFR (ml/min/1.73m2)
Serum potassium (mmol/L)
Figure.  A, Serum potassium (mmol/L) kinetics between treatment groups. B, Estimated glomerular filtration rate (eGFR; mL/min per 1.73 
m2) kinetics between treatment groups. C, Pearson correlation coefficient of eGFR vs serum potassium by time.
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which is consistent with our previous observations from the 
Eplerenone Post-Acute Myocardial Infarction Heart Failure 
Efficacy and Survival study (EPHESUS).2 A similar eGFR 
kinetics was observed generally in patients with more severe 
HF enrolled in Randomized ALdactone Evaluation Study 
(RALES).12 A functional hemodynamic effect because of 
blockade of the RAAS is presumably involved15 in the early 
eGFR decline observed in the 3 MRA studies because no fur-
ther subsequent deterioration occurred over time.
In the present study, we report that, under close monitor-
ing, episodes of WRF were common during follow-up and 
were associated with higher mortality and hospitalization 
rates. This finding is consistent with previous reports showing 
that WRF during hospitalization or shortly after discharge is 
a major independent risk factor for mortality in patients with 
postinfarction left ventricular dysfunction and HF, as shown in 
the SAVE (Survival and Ventricular Enlargement), VALIANT 
(VALsartan In Acute myocardial iNfarcTion), and EPHESUS 
Table 2. Relationship of the Risk of Hyperkalemia With First Occurrence of Worsening Renal Function as Time-Dependant 
Covariate Using a Multivariate Cox Model Adjusting for Baseline Covariates
WRF (eGFR Decrease >20%) WRF (eGFR Decrease >30%)
HK>4.5 HK>5.0 HK>5.5 HK>4.5 HK>5.0 HK>5.5
Events/Patients 1959/2624 881/2711 243/2734 1959/2624 881/2711 243/2734
WRF 1.21 (0.95–1.55) 1.58 (1.27–1.97) 2.23 (1.56–3.19) 1.53 (1.09–2.15) 1.45 (1.07–1.97) 2.47 (1.61–3.78)
P=0.13 P<0.001 P<0.001 P=0.015 P=0.015 P<0.001
BL eGFR ≤ median (68  
mL/min per 1.73 m2)
NA 1.28 (1.12–1.46) 1.77 (1.36–2.30) NA 1.26 (1.10–1.44) 1.73 (1.33–2.25)
P<0.001 P<0.001 P<0.001 P<0.001
BL K> 4.5 mmol/L NA 2.42 (2.12–2.76) 2.56 (1.98–3.31) NA 2.41 (2.11–2.75) 2.54 (1.96–3.28)
P<0.001 P<0.001 P<0.001 P<0.001
Hypertension NA 1.23 (1.06–1.42) 1.69 (1.25–2.29) NA 1.23 (1.06–1.42) 1.7 (1.26–2.30)
P=0.006 P<0.001 P=0.006 P<0.001
Eplerenone 1.28 (1.17–1.40) 1.51 (1.32–1.73) 1.67 (1.29–2.17) 1.28 (1.17–1.40) 1.51 (1.32–1.73) 1.67 (1.29–2.16)
P<0.001 P<0.001 P<0.001 P<0.001 P<0.001 P<0.001
White ethnicity NA NA 0.71 (0.50–1.00) NA NA 0.71 (0.50–1.01)
P=0.052 P=0.055
Values are hazard ratio (95% confidence interval) and P value. BL indicates baseline; eGFR, estimated glomerular filtration rate; HK, hyperkalemia; K, kalemia; NA, 
not applicable; and WRF, worsening renal function.
Table 3. Relationship of Risk of Worsening Renal Function With First Occurrence of Hyperkalemia as Time-Dependant Covariate: 
Multivariate Cox Model Adjusting for Baseline Covariates
HK>4.5 mmol/L HK>5.0 mmol/L HK>5.5 mmol/L
WRF (>20%) WRF (>30%) WRF (>20%) WRF (>30%) WRF (>20%) WRF (>30%)
Events/Patients 745/2736 384/2736 745/2736 384/2736 745/2736 384/2736
Hyperkalemia 1.00 (0.85–1.18) 1.26 (0.99–1.61) 1.24 (1.05–1.46) 1.67 (1.35–2.07) 1.37 (1.03–1.82) 1.51 (1.06–2.16)
P=1.00 P=0.064 P=0.011 P<0.001 P=0.029 P=0.024
Age ≥75 y 1.54 (1.31–1.81) 1.70 (1.37–2.12) 1.55 (1.32–1.82) 1.72 (1.38–2.15) 1.54 (1.31–1.82) 1.70 (1.36–2.12)
P<0.001 P<0.001 P<0.001 P<0.001 P<0.001 P<0.001
BL eGFR ≤median (68  
mL/min per 1.73 m2)
0.60 (0.52–0.70) 0.70 (0.57–0.87) 0.60 (0.51–0.70) 0.69 (0.56–0.85) 0.60 (0.51–0.70) 0.70 (0.57–0.86)
P<0.001 P<0.001 P<0.001 P<0.001 P<0.001 P<0.001
Diabetes mellitus 1.41 (1.22–1.64) 1.43 (1.16–1.76) 1.40 (1.21–1.63) 1.40 (1.13–1.72) 1.41 (1.22–1.64) 1.43 (1.16–1.76)
P<0.001 P<0.001 P<0.001 P=0.002 P<0.001 P<0.001
Ejection fraction <30% 1.19 (1.01–1.40) NA 1.19 (1.01–1.40) NA 1.19 (1.01–1.40) NA
P=0.038 P=0.039 P=0.040
Eplerenone 1.22 (1.06–1.42) 1.28 (1.05–1.57) 1.21 (1.04–1.39) 1.26 (1.03–1.54) 1.21 (1.05–1.40) 1.29 (1.06–1.59)
P=0.006 P=0.016 P=0.012 P=0.026 P=0.009 P=0.013
Antiarrthymics 1.34 (1.10–1.64) 1.39 (1.06–1.84) 1.34 (1.10–1.65) 1.40 (1.06–1.85) 1.34 (1.10–1.64) 1.40 (1.06–1.85)
P=0.004 P=0.018 P=0.004 P=0.016 P=0.004 P=0.017
Diuretics 1.27 (1.03–1.57) NA 1.28 (1.04–1.58) NA 1.27 (1.02–1.56) NA
P=0.027 P=0.022 P=0.029
Values are hazard ratio (95% confidence interval) and P value. BL indicates baseline; eGFR, estimated glomerular filtration rate; HK, hyperkalemia; NA, not applicable; 
and WRF, worsening renal function.
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trials.2,16,17 Similarly, a meta-analysis of 8 studies represent-
ing 18 634 patients showed that an increase in serum creati-
nine >0.2 mg/dL (17.6 μmol/L) or a corresponding decrease 
in eGFR >5 mL/min per 1.73 m2 was associated with a 62% 
increase in mortality in both  in-hospital patients and ambu-
latory patients.4 However, all previous reports were focused 
on the prognostic significance of WRF considered separately 
from HK. Importantly, we show for the first time that the 
occurrence of WRF (defined as a >20% or >30% decrease 
in eGFR) is associated with adverse outcomes independently 
from HK.
Patients with HF are particularly susceptible to HK 
because the reduction in renal function frequently associated 
with HF, older age, and comorbidities, such as diabetes mel-
litus and RAAS blockade hampers baseline potassium excre-
tion.18,19 In an analysis of patients enrolled in the Candesartan 
in Heart Failure Assessment of Reduction in Mortality and 
Morbidity (CHARM) program in which a broad spectrum 
of patients with HF were randomized to treatment with can-
desartan or placebo in addition to optimal medical therapy, 
Desai et al18 identified age, diabetes mellitus, renal dysfunc-
tion (creatinine ≥2.0 mg/dL), starting serum potassium ≥5.0 
mEq/L, background therapy with angiotensin-converting 
enzyme inhibitor or spironolactone, and randomization to 
the angiotensin receptor blocker as multivariable predic-
tors of clinically important HK. In an EPHESUS post hoc 
analysis, 4 independent baseline predictors of HK (defined 
as ≥6.0 mEq/L) were identified: baseline potassium greater 
than the median (4.3 mEq/L), baseline eGFR ≤60 mL/min 
per 1.73 m2, history of diabetes mellitus, and previous use 
of antiarrhythmic agents. None of these independent baseline 
risk factors significantly affected the cardiovascular benefit 
of eplerenone for reducing all-cause mortality.19 In the pres-
ent study, a history of hypertension, eplerenone use, higher 
baseline serum potassium concentrations (>4.5 mmol/L) and 
lower baseline eGFR (as well as nonwhite ethnicity for HK 
>5.5 mmol/L), and WRF onset were identified as indepen-
dent predictors of the occurrence of HK >5 and >5.5 mmol/L. 
Furthermore, HK >5.5 mmol/L was an independent predictor 
of outcomes, even after adjustment for baseline predictors of 
WRF and HK and the occurrence of WRF.
The occurrence of HK or of WRF did not hinder the major 
clinical benefits of eplerenone most likely because of the care-
ful management of rises in potassium, dosing algorithm, and 
serum potassium and creatinine monitoring regimen used 
in the present clinical trial that are, therefore, to be strongly 
Table 4. Relationship of Risk of Hyperkalemia, Worsening Renal Function, and Treatment Group With 
Clinical Outcomes Using a Multivariate Cox model Adjusting for Baseline Covariates
HF Hospitalization/CV Death 
(n/N, 604/2736)
HF Hospitalization 
(n/N, 417/2736)
CV Death  
(n/N, 331/2736)
All-Cause Death 
(n/N, 383/2736)
HK>4.5 mmol/L 0.86 (0.72–1.03) 0.86 (0.69–1.06) 0.80 (0.63–1.01) 0.83 (0.66–1.03)
WRF>20% 1.30 (1.03–1.63) 1.43 (1.09–1.88) 1.34 (1.01–1.77) 1.38 (1.07–1.78)
EPL 0.64 (0.55–0.76) 0.60 (0.49–0.73) 0.77 (0.62–0.95) 0.77 (0.63–0.95)
HK>5.0 mmol/L 1.08 (0.90–1.31) 0.97 (0.77–1.23) 1.08 (0.85–1.39) 1.07 (0.85–1.35)
WRF>20% 1.28 (1.02–1.61) 1.42 (1.08–1.87) 1.31 (0.99–1.74) 1.36 (1.05–1.75)
EPL 0.63 (0.54–0.74) 0.59 (0.48–0.72) 0.74 (0.60–0.93) 0.75 (0.61–0.92)
HK>5.5 mmol/L 1.20 (0.89–1.61) 1.10 (0.76–1.60) 1.37 (0.95–1.98) 1.40 (1.01–1.96)
WRF>20% 1.28 (1.02–1.61) 1.41 (1.07–1.86) 1.31 (0.99–1.73) 1.35 (1.04–1.74)
EPL 0.63 (0.54–0.74) 0.59 (0.48–0.72) 0.74 (0.59–0.92) 0.75 (0.61–0.91)
HK>4.5 mmol/L 0.86 (0.72–1.03) 0.86 (0.69–1.06) 0.79 (0.62–1.01) 0.82 (0.65–1.03)
WRF>30% 1.55 (1.17–2.07) 1.43 (0.99–2.05) 1.53 (1.08–2.16) 1.69 (1.24–2.30)
EPL 0.64 (0.54–0.76) 0.60 (0.49–0.73) 0.77 (0.61–0.95) 0.77 (0.63–0.94)
HK>5.0 mmol/L 1.08 (0.89–1.30) 0.98 (0.77–1.23) 1.08 (0.84–1.38) 1.07 (0.85–1.34)
WRF>30% 1.52 (1.14–2.02) 1.41 (0.98–2.03) 1.49 (1.05–2.10) 1.65 (1.21–2.25)
EPL 0.63 (0.53–0.74) 0.59 (0.49–0.72) 0.74 (0.60–0.92) 0.75 (0.61–0.92)
HK>5.5 mmol/L 1.19 (0.88–1.60) 1.11 (0.76–1.60) 1.36 (0.95–1.97) 1.39 (0.99–1.94)
WRF>30% 1.51 (1.13–2.01) 1.40 (0.97–2.01) 1.47 (1.04–2.08) 1.63 (1.20–2.22)
EPL 0.63 (0.53–0.74) 0.59 (0.48–0.72) 0.74 (0.59–0.92) 0.74 (0.61–0.91)
Adjusted for treatment group, age (<75 and ≥75 y), baseline estimated glomerular filtration rate (≤median and >median), diabetes 
mellitus, presence of left bundle branch block, sex, mean arterial pressure (≤median and >median), use of potassium supplements, 
target dose of β-blockers at randomization (<50% and ≥50%), use of antiarrhythmics, use of diuretics, and ethnicity (white vs other). 
Values are hazard ratio (95% confidence interval). CV indicates cardiovascular; EPL, eplerenone vs placebo; HF, heart failure; HK, 
hyperkalemia; and WRF, worsening renal function from baseline.
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recommended in clinical practice to retrieve the positive ben-
efit/risk ratio achieved by eplerenone in EMPHASIS-HF. This 
happened even in subgroups of patients at high risk of HK 
or WRF (ie, patients ≥75 years, with diabetes mellitus, with 
eGFR<60 mL/min per 1.73 m2, and with systolic blood pres-
sure <median of 123 mm Hg).20 Interestingly, in patients with 
HF enrolled in RALES although WRF during the titration 
phase (WRF occurring later being not studied herein) occurred 
more frequently in patients randomized to spironolactone, the 
risk associated with this worsening was greatest in patients in 
the placebo group and was markedly attenuated in those tak-
ing spironolactone.12 Therefore, the present EMPHASIS-HF 
analysis, considering the occurrences of HK and WRF (with 
several cutoffs used), anytime corroborate and expand our pre-
vious conclusions.
Limitations
First, our analysis was post hoc. However, the present data 
were derived from a large randomized controlled trial with 
rigorous collection of serum creatinine, serum potassium, and 
clinical events adjudicated by an end point committee. These 
results were obtained in patients with HF and a reduced EF, 
mild symptoms, and serum potassium <5 mmol/L, eGFR >30 
mL/min per 1.73 m2 at entry; there was frequent biochemical 
monitoring during follow-up. Therefore, the external validity 
and potential generalizability to real-world patients with HF 
is uncertain. Importantly, however, the determinants of WRF 
and HK in EMPHASIS-HF were similar to those identified in 
other HF populations. Finally, the present results were based 
on estimated GFR, using the MDRD (Modification of Diet 
in Renal Disease) formula, which accurately estimates kidney 
function in patients with HF,21 with an eGFR <60 mL/min per 
1.73 m2 but maybe not in others.
Conclusions
In summary, our data provide critical practical insights into 
long-term cardiorenal interactions and outcomes in patients 
with left ventricular systolic dysfunction with mild symp-
toms receiving RAAS inhibitor and MRA therapy. Episodes 
of HK or WRF were common in patients receiving optimal 
therapy, including angiotensin-converting enzyme inhibitor or 
angiotensin receptor blockers and β-blockers. The addition of 
eplerenone increased the rate of WRF and HK. Both types of 
adverse events may pose a therapeutic dilemma in daily prac-
tice because the patients at highest risk for these complications 
are the patients who derive the greatest absolute cardiovascu-
lar benefit from RAAS inhibitors and MRAs.7 However, and 
most importantly, these adverse outcomes did not negate the 
major survival benefit of eplerenone when electrolyte and kid-
ney function were systematically monitored, and eplerenone 
doses were adjusted based on renal function and potassium 
concentration.
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CLINICAL PERSPECTIVE
Episodes of hyperkalemia or worsening renal function were common in patients with systolic heart failure and mild symp-
toms receiving optimal therapy, including angiotensin-converting enzyme inhibitor or angiotensin receptor blockers and 
β-blockers. The addition of eplerenone increased the rate of worsening renal function and hyperkalemia. Both types of 
adverse events may pose a therapeutic dilemma in daily practice because the patients at highest risk for these complications 
are the patients who derive the greatest absolute cardiovascular benefit from renin angiotensin aldosterone system inhibitors, 
including mineralocorticoid receptor antagonists. However, and most importantly, these adverse outcomes did not negate the 
major survival benefit of eplerenone, when electrolyte and kidney function were systematically monitored, and eplerenone 
doses were adjusted based on renal function and potassium concentration.
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SUPPLEMENTAL MATERIAL 
Supplemental data on Table 4: interactions with treatment group 
 
Supplemental Table 4A: Multivariate cox model adjusting for baseline covariates: Relationship of risk of HF hospiltalization/CV death with HK and WRF 
(eGFR decrease>20%): tests for HK by risk factor interactions* 
 
                                                     K>4.5 mmol/L             K>5.0 mmol/L             K>5.5 mmol/L 
                                            ------------------------  ------------------------  ------------------------ 
                                                HR       interaction      HR       interaction      HR       interaction 
  risk factor               category         (95% ci)      p value     (95% ci)      p value     (95% ci)      p value 
  ---------------------------------------------------------------------------------------------------------------------- 
 
   
 
  treatment group           placebo             ---         0.485         ---         0.466         ---         0.320 
                            eplerenone          ---                       ---                       --- 
 
* HK and WRF as time dependent covariates adjusted for risk factors 
 
 
Supplemental Table 4B: Multivariate cox model adjusting for baseline covariates: Relationship of risk of HF hospitalization/CV death with HK and WRF (eGFR 
decrease>30%): tests for HK by risk factor interactions* 
 
                                                     K>4.5 mmol/L             K>5.0 mmol/L            K>5.5 mmol/L 
                                            ------------------------  ------------------------  ------------------------ 
                                                HR       interaction      HR       interaction      HR       interaction 
  risk factor               category         (95% ci)      p value     (95% ci)      p value     (95% ci)      p value 
  ---------------------------------------------------------------------------------------------------------------------- 
 
   
 
  treatment group           placebo             ---         0.530         ---         0.563         ---         0.373 
 
   
  treatment group           eplerenone          ---                       ---                       --- 
  * HK and WRF as time dependent covariates adjusted for risk factors 
   
Supplemental Table 4C: Multivariate cox model adjusting for baseline covariates : Relationship of risk of HF hospitalization/cv death with HK and WRF(eGFR 
decrease>20%): tests for WRF by risk factor interactions* 
 
                                                     K>4.5 mmol/L           K>5.0  mmol/L             K>5.5 mmol/L 
                                            ------------------------  ------------------------  ------------------------ 
                                                HR       interaction      HR       interaction      HR      interaction 
  risk factor               category         (95% ci)      p value     (95% ci)      p value     (95% ci)      p value 
  ---------------------------------------------------------------------------------------------------------------------- 
 
 
  treatment group           placebo             ---         0.337         ---         0.314         ---         0.308 
                            eplerenone          ---                       ---                       --- 
 
* HK and WRF as time dependent covariates adjusted for risk factors
 
Supplemental Table 4D: Multivariate cox model adjusting for baseline covariates: Relationship of risk of HF hospitalization/CV death with HK and WRF(eGRF 
decrease>30%): tests for WRF by risk factor interactions* 
 
                                                     K>4.5  mmol/L                   K>5.0 mmol/L        K>5.5 mmol/L 
                                            ------------------------  ------------------------  ------------------------ 
                                                HR      interaction      HR       interaction      HR       interaction 
  risk factor               category         (95% ci)      p value     (95% ci)      p value     (95% ci)      p value 
  ---------------------------------------------------------------------------------------------------------------------- 
 
   
 
  treatment group           placebo             ---         0.725         ---         0.716         ---         0.699 
                            eplerenone          ---                       ---                       --- 
 
 
 
  
* HK and WRF as time dependent covariates adjusted for risk factors 
 
